In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, AbCellera Biologics Inc (NASDAQ: ABCL) closed at $3.69 down -0.81% from its previous closing price of $3.72. In other words, the price has decreased by -$0.81 from its previous closing price. On the day, 2.7 million shares were traded. ABCL stock price reached its highest trading level at $3.82 during the session, while it also had its lowest trading level at $3.66.
Ratios:
For a deeper understanding of AbCellera Biologics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.10 and its Current Ratio is at 10.10. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1104546304 and an Enterprise Value of 751092352. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.27 while its Price-to-Book (P/B) ratio in mrq is 1.14. Its current Enterprise Value per Revenue stands at 21.262 whereas that against EBITDA is -3.228.
Stock Price History:
The Beta on a monthly basis for ABCL is 0.73, which has changed by 0.22772276 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, ABCL has reached a high of $6.51, while it has fallen to a 52-week low of $1.89. The 50-Day Moving Average of the stock is -14.30%, while the 200-Day Moving Average is calculated to be -0.33%.
Shares Statistics:
For the past three months, ABCL has traded an average of 4.95M shares per day and 3151120 over the past ten days. A total of 299.01M shares are outstanding, with a floating share count of 230.95M. Insiders hold about 22.84% of the company’s shares, while institutions hold 35.89% stake in the company. Shares short for ABCL as of 1764288000 were 50842609 with a Short Ratio of 10.28, compared to 1761868800 on 55161166. Therefore, it implies a Short% of Shares Outstanding of 50842609 and a Short% of Float of 22.03.
Earnings Estimates
The performance of AbCellera Biologics Inc (ABCL) in the stock market is under the watchful eye of 4.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.18 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.61 and -$0.71 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.69, with 3.0 analysts recommending between -$0.62 and -$0.8.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $6.28M this quarter.It ranges from a high estimate of $9.28M to a low estimate of $3.95M. As of. The current estimate, AbCellera Biologics Inc’s year-ago sales were $5.1MFor the next quarter, 7 analysts are estimating revenue of $14.43M. There is a high estimate of $33.53M for the next quarter, whereas the lowest estimate is $7.58M.
A total of 9 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $39.56M, while the lowest revenue estimate was $34.22M, resulting in an average revenue estimate of $36.06M. In the same quarter a year ago, actual revenue was $28.83MBased on 7 analysts’ estimates, the company’s revenue will be $56.31M in the next fiscal year. The high estimate is $176.87M and the low estimate is $29.04M.
